多西他赛和吉西他滨分别联合顺铂治疗晚期非小细胞肺癌效果比较

Study of the efficacy and safety of docetaxel plus cisplatin and gemcitabine plus cisplatin in advanced non-small cell lung cancer

目的 比较多西他赛与吉西他滨联合顺铂方案治疗晚期非小细胞肺癌（NSCLC）的临床疗效及不良反应.方法 120例晚期非小细胞肺癌患者完全随机分为2组.多西他赛组60例给予多西他赛37.5 mg/m2,第1、8天;顺铂25 mg/m2,第1～3天.吉西他滨组60例给予吉西他滨1000 mg/m2,第1、8天;顾铂用量同前.化疗每3周重复,每周期评价不良反应,评价疗效并随访生存期.结果 20例患者均可评价疗效和不良反应,2组有效率分别为多西他赛组45.0%（27/60）和吉西他滨组43.3%（26/60）,1年生存率分别为45%和43.3%,两组之间有效率和1年生存率均无统计学意义（P＞0.05）.不良反应主要为骨髓抑制和肝功能损害[多西他赛组白细胞产减少率为85.0%（51/60）,吉西他滨组为78.0%（47/60）,2组差异无统计学意义（P＞0.05）;2组肝功能损害率分别为33.3%（20/60）、26.7%（16/60）,差异有统计学意义（P＜0.05）].结论 多西他赛与吉西他滨联合顺铂方案治疗晚期NSCLC均具有较好的疗效,且两者的疗效相似,不良反应可以耐受,可以作为临床一线治疗.

Objective To compare the efficacy and safety of docetaxel plus cisplatin and gemcitabine plus cisplatin in advanced non-small cell lung cancer （NSCLC）. Methods A total of 120 patients with advanced NSCLC were divided into two groups. The patients received docetaxel in docetaxel group. In gemcitabine group the patients received gemcitabine and cisplatin. The treatment schedule was repeated every 3 weeks. The toxicity,quality response and survival rate of life were evaluated after every cycle. Results The response rates of the docetaxel group and the gemcitabine group were 45% and 43.3%,respectively. One-year survival rates in the two groups were 45% and 43.3%,respectively. The response rate,one-year survival time showed no significance （P 〉0.05）. The main side effects were myelosupp ression,nausea and vomiting. Conclusion Regimens of DC and GC are both safe and effective in the treatment of advanced stage NSCLC. They can be used as the first regimen of chemotherapy in patients with advanced stage NSCLC.